Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Morton Toe and Neuromuscular Performance

8. mai 2026 oppdatert av: Nihat Sarıalioğlu, Giresun University

Morton Toe is Associated With Faster Contractile Properties and Superior Reactive Strength in Female Football Players

This cross-sectional observational study investigated whether female football players with Morton toe morphology differ from those with normal foot morphology in neuromuscular contractile properties and kinetic performance characteristics. Morton toe is a congenital foot variation in which the second toe is longer than the first. A total of 47 female football players were classified into two groups based on bilateral foot morphology: Morton foot group (n = 24) and normal foot group (n = 23). Neuromuscular properties of the dominant vastus lateralis muscle were assessed using tensiomyography, and kinetic performance was evaluated through a 40-cm drop jump test on dual force plates. The primary outcomes were contraction time (Tc) and reactive strength index (RSI). Secondary outcomes included relaxation time, delay time, sustain time, maximal displacement, jump height, peak power normalized to body mass, and landing net peak force normalized to body mass. Multiple linear regression models adjusted for age, body mass index, and mean arch index were used to evaluate whether group differences were independent of potential confounders. This study aimed to determine whether Morton toe morphology is associated with distinct neuromuscular and kinetic performance profiles in female athletes.

Studieoversikt

Detaljert beskrivelse

Morton toe is a congenital foot morphology characterized by a longer second metatarsal relative to the first. Although traditionally regarded as a clinical or orthopedic variation associated with metatarsal stress fractures and balance difficulties, limited evidence from sprinter populations suggests that a longer second toe may be associated with superior athletic performance. However, no previous study has examined whether Morton toe morphology is related to neuromuscular contractile properties assessed via tensiomyography or kinetic performance derived from force plate testing in a controlled group comparison design.

Participants were screened from 97 female football players. Exclusion criteria included BMI outside the 18.5-29.9 range, bilateral arch index outside the 14-29% range, inconsistent bilateral foot morphology, lower-extremity injury within the past 12 months, neurological or orthopedic conditions, performance-affecting pharmacological use, and menstruation on the measurement day. Morton toe classification was based on the palpation method described by Davidson et al. (2007) with a minimal detectable change threshold of ±0.30 mm.

All measurements were conducted during the off-season to minimize training load interference. Testing followed a standardized sequence: foot morphology assessment, tensiomyography of the dominant vastus lateralis at rest, a 15-minute warm-up, and a 40-cm drop jump test. The assessor was blinded to group classification, and statistical analysis was performed by an independent researcher on a coded dataset. Primary outcome variables (Tc and RSI) were determined a priori. Secondary outcomes were corrected for multiple comparisons using the Holm-Bonferroni method. Regression analyses were performed to assess the independence of group effects from age, body mass index, and mean bilateral arch index.

Studietype

Observasjonsmessig

Registrering (Faktiske)

47

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Centre
      • Giresun, Centre, Tyrkia (Türkiye), 28100
        • Giresun University - Sports Science Faculty

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Female football players actively competing in organized leagues in Turkey, recruited from multiple teams during the 2025-2026 off-season period. A total of 97 players were initially screened; 47 met all eligibility criteria and were classified into Morton foot (n=24) and normal foot (n=23) groups.

Beskrivelse

Inclusion Criteria:

  • Active female football players with a valid sports license for the current season
  • Regular participation in training and competitive matches
  • Bilateral Morton toe morphology (Δ ≤ -0.30 mm on both feet) or bilateral normal foot morphology (Δ > +0.30 mm on both feet)
  • Body mass index between 18.5 and 29.9 kg/m²
  • Bilateral arch index between 14% and 29%
  • Voluntary participation with written informed consent

Exclusion Criteria:

  • Serious lower-extremity musculoskeletal injury within the past 12 months
  • Neurological or orthopedic disease affecting measurement procedures
  • Current use of pharmacological products affecting performance
  • Acute pain, injury, or illness on the measurement day
  • Menstruation on the measurement day (self-reported)
  • Inconsistent bilateral foot morphology classification between feet
  • Bilateral arch index below 14% (high arch) or above 29% (low arch)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Morton Foot Group
Female football players with bilateral Morton toe morphology, defined as a second metatarsal protrusion distance exceeding the first by more than 0.30 mm bilaterally (Δ ≤ -0.30 mm). n = 24.
Normal Foot Group
Female football players with bilateral normal foot morphology, defined as a first metatarsal protrusion distance exceeding the second by more than 0.30 mm bilaterally (Δ > +0.30 mm). n = 23.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Contraction Time (Tc)
Tidsramme: Single measurement session
Tensiomyographic contraction time of the dominant vastus lateralis muscle, defined as the time between 10% and 90% of maximal radial displacement (ms).
Single measurement session
Reactive Strength Index (RSI)
Tidsramme: Single measurement session
Jump height divided by ground contact time during a 40-cm drop jump test (m/s). The trial with the highest RSI value out of three attempts was selected for analysis.
Single measurement session

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximal Displacement (Dm)
Tidsramme: Single measurement session
Peak radial displacement of the vastus lateralis muscle belly during tensiomyographic measurement (mm).
Single measurement session
Relaxation Time (Tr)
Tidsramme: Single measurement session
Time from 90% to 50% of maximal displacement during the relaxation phase of tensiomyographic measurement (ms).
Single measurement session
Delay Time (Td)
Tidsramme: Single measurement session
Time from electrical stimulus onset to 10% of maximal displacement during tensiomyographic measurement (ms).
Single measurement session
Sustain Time (Ts)
Tidsramme: Single measurement session
Duration the muscle response remains above 50% of maximal displacement during tensiomyographic measurement (ms).
Single measurement session
Jump Height (JH)
Tidsramme: Single measurement session
Vertical jump height calculated from flight time during a 40-cm drop jump test (cm).
Single measurement session
Peak Power Normalized to Body Mass (PPI)
Tidsramme: Single measurement session
Peak power output normalized to body mass during a 40-cm drop jump test (W/kg).
Single measurement session
Landing Net Peak Force Normalized to Body Mass (LPF)
Tidsramme: Single measurement session
Peak vertical ground reaction force at landing normalized to body mass during a 40-cm drop jump test (N/kg).
Single measurement session

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. januar 2026

Primær fullføring (Faktiske)

15. mars 2026

Studiet fullført (Faktiske)

15. mars 2026

Datoer for studieregistrering

Først innsendt

8. mai 2026

Først innsendt som oppfylte QC-kriteriene

8. mai 2026

Først lagt ut (Faktiske)

14. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere